Second-Line Combination Chemotherapy with Docetaxel and Nedaplatin for Cisplatin-Pretreated Refractory Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

Jin, Jianhua; Xu, Ximing; Wang, Fang; Yan, Guoquan; Liu, Jianyue; Lu, Wenbin; Li, Xianwen; Tucker, Steven; Zhong, Bao‐Liang; Cao, Zhigang; Wang, Daoyuan

doi:10.1097/jto.0b013e3181add9c7

Cited by 39 publications

(37 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous cancers, including nasopharyngeal cancer, NSCLC, esophageal cancer, urothelial carcinoma and cervical cancer, have been reported to be effective to NDP-based chemotherapy in clinical studies (7)(8)(9)(10)(11)(12)(13). However, the majority of recent studies have focused on the therapeutic effect of NDP on esophageal cancer, although this type of cancer does not respond well to platinum-based chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer

Shan

Xiong

Wang

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Nedaplatin (NDP) has been extensively used to treat patients with non-small cell lung cancer (NSCLC) in the last decade. The present study compared the survival benefits of NDP and cisplatin (DDP) in the treatment of NSCLC. Patients (n=392) with NSCLC were treated with at least two cycles of platinum-based chemotherapy. Among these patients, 202 received DDP-based chemotherapy, and 190 received NDP-based chemotherapy. The overall survival time of the two groups and the toxicity of drugs were analyzed. The results showed that only the chemotherapy cycle duration was found to be statistically different between DDP and NDP groups in all the characteristics. The mean chemotherapy duration was 3.3 cycles in the DDP group, and 4.1 cycles in the NDP group (χ 2 =20.206, P<0.001). Additionally, the chemotherapy cycle number was also an independent predictive factor for the overall survival time in the multivariate analysis (HR=0.539, P<0.001). The median survival time (MST) was 15 months in the DDP group, and 20 months in the NDP group (χ 2 =5.189, P=0.023). The 1-, 2-and 3-year overall survival rates were 62.4, 25.7 and 15.8%, and 78.9, 38.9, and 16.8% in the DPP and NDP groups, respectively. The incidence of grade 3-4 nausea/vomiting, anorexia and weight loss was higher in the DDP compared to the NDP group (36.1 vs. 8.4%, 17.3 vs. 5.8%, and 9.9 vs. 1%, respectively). In conclusion, NDP-based chemotherapy had a survival benefit compared to DDP-based chemotherapy for NSCLC patients, due to the lower toxicity of NDP, which renders this drug more tolerable, thus allowing patients to undergo more cycles of chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer

Shan

Xiong

Wang

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Apart from response rates, the time to progression was short in most studies, being less than 4 months in 13 trials and being not stated in another five of 27 trials (Cuningham et al, 2008;Nakajima et al, 2008;Jin et al, 2009).…”

Section: Discussionmentioning

confidence: 94%

Retrospective Study of Gemcitabine Based Chemotherapy for Unresectable or Recurrent Esophagus Squamous Cell Carcinoma Refractory to First Line Chemotherapy

Wang

Gu²,

Wang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To investigate the efficacy and toxicity of a combination of gemcitabine with nedaplatin (GN) or cisplatin (GC) for patients with unresectable or recurrent esophagus squamous cell carcinoma. Methods: Gemcitabine was administered at 1 g/m 2 intravenously on days 1 and 8; and nedaplatin or cisplatin were administered at 80 mg/m 2 intravenously on day 1. We analyzed the response rate, overall survival time, progression-free survival time, and toxicity in 21 patients treated with GN and 27 patients treated with GC. Results: In patients treated with gemcitabine plus nedaplatin, the ORR was 47.6%, the median progression-free survival time was 4.1 months, and the median survival time was 9.3 months. In patients treated with gemcitabine plus cisplatin, the ORR was 48.2%, the median progression-free survival time was 3.9 months, and the median survival time was 9.1 months, respectively. There were no statistically significant differences in ORR, PFS and OS between the two groups. In both, the most commonly observed toxicities were thrombocytopenia and fatigue. Nausea and vomiting was more frequent in the GC group than in the GN group. Conclusion: Gemcitabine based chemotherapy was effective and tolerable for patients with unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy.

show abstract

“…Nedaplatin (NDP), which is a second-generation DDP analog, was developed by the Shionogi Pharmaceutical Company (Japan) in 1983, in order to provide a treatment with a level of effectiveness similar to that of DDP, but with decreased gastrointestinal and renal toxicities (12). A number of previous clinical studies have demonstrated the efficacy of NDP to be higher than that of DDP in patients with DDP-resistant lung cancer (13,14). Conversely, there are comparatively few in vitro studies to support the consensus.…”

Section: Introductionmentioning

confidence: 98%

Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells

et al. 2016

View full text Add to dashboard Cite

Abstract. Cisplatin (DDP) has been one of the most widely used chemotherapy drugs for advanced non-small cell lung cancer. However, the increase in the number of DDP-resistant cancer cells has become a major impediment in the clinical management of cancer. In the present study, for the first time, the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide assay was used to demonstrate that nedaplatin (NDP) could have a stronger inhibitory effect than DDP alone in DDP-resistant A549 (A549DDP) cells and that it could attenuate the resistance of these cells. Additionally, flow cytometry analysis showed that the apoptosis rate of these resistant cells when exposed to NDP was markedly increased and the number of cells in the G2 stage of the cell cycle was significantly increased. Furthermore, western blot analysis indicated that NDP decreased the protein expression of P-glycoprotein, tumor protein p53 and B-cell lymphoma 2, and increased the expression of Bcl-2-associated X protein, all of which could possibly improve the NDP intracellular drug concentration and promote cell apoptosis. These observations suggested that NDP could have higher efficacy in DDP-resistant lung cancer cells, and further studies applying more detailed analyses are warranted to elucidate the mechanism(s) behind this effect.

show abstract

Second-Line Combination Chemotherapy with Docetaxel and Nedaplatin for Cisplatin-Pretreated Refractory Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

Abstract: The combination chemotherapy of docetaxel and nedaplatin in the outpatient setting is well tolerated and useful as second-line chemotherapy for cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.

Cited by 39 publications

References 25 publications

Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer

Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer

Retrospective Study of Gemcitabine Based Chemotherapy for Unresectable or Recurrent Esophagus Squamous Cell Carcinoma Refractory to First Line Chemotherapy

Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells

Contact Info

Product

Resources

About